Difference between revisions of "Tisagenlecleucel (Kymriah)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 25: | Line 25: | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2017]] |
Revision as of 19:21, 30 July 2018
Mechanism of action
From the NCI Drug Dictionary: Autologous T lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel direct the T lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells.
Link to REMS program
Diseases for which it is used
History of changes in FDA indication
- 8/30/2017: Granted FDA regular approval "for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse."
- 5/1/2018: FDA approval expanded "for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma."
Also known as
- Code name: CTL019
- Generic name: tisagenlecleucel-T
- Brand name: Kymriah